Guizhou Bailing Group Pharmaceutical (002424.SZ): The clinical trial application for Tangning Tongluo Tablets has been approved.

Guizhou Bailing Group Pharmaceutical (002424.SZ) announced that its wholly-owned subsidiary, Bailin Yuxiu (Zhuhai) Pharmaceutical Co., Ltd. (referred to as "Bailin Yuxiu"), has received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration (NMPA). The application for the clinical trial of Tangning Tongluo Tablets submitted by Bailin Yuxiu has been approved, allowing the product to be used in clinical trials for type 2 diabetes.